

NEWSLETTER

CHEMICAL & PHARMACEUTICAL

3 – 9 August 2026



NMPA Grants Marketing Approval To Henlius Serplulimab For Perioperative Gastric Cancer Treatment

China has approved Hansoh BioLOGICS' anti-PD-1 monoclonal antibody serplulimab (brand name HANSIZHUANG) for neoadjuvant and adjuvant therapy in resectable gastric cancer patients with PD-L1 CPS $\geq$ 5. Phase III ASTRUM-006 data showed a 33% reduction in disease progression or recurrence risk and a pathologic complete response rate of 21.6%, triple that of conventional chemotherapy. **(National Medical Products Administration)**

China's First Domestically Developed Alk Inhibitor Conmetinib Approved For First-Line Nsclc Treatment

China granted marketing authorization to Firstgene Holding's Category 1 innovative small-molecule ALK inhibitor conmetinib granules (trade name SHOUYAOZE) for previously untreated ALK-positive advanced non-small cell lung cancer. Pivotal trials demonstrated superior progression-free survival compared with first-generation ALK inhibitors and favorable CNS penetration for intracranial metastatic lesions. **(National Medical Products Administration)**

CNCEC Signs \$2.3 Billion Coal-to-Methanol Strategic Project in Indonesia

China National Chemical Engineering Group (CNCEC) signed agreements for a \$2.3 billion coal-to-methanol project in East Kalimantan, Indonesia. Designated as an Indonesian national strategic project, the facility will produce 2 million tons of methanol annually using local low-calorific coal, showcasing China's expanding export of advanced coal-chemical engineering technology. **(ChemNet Chemical Headlines)**

Sinopec Launches World's Largest Single-Site High-End PVA Base

Sinopec's Chongqing SVW Chemical successfully commissioned a new 50,000-ton high-end polyvinyl alcohol (PVA) unit, bringing its total capacity to 210,000 tons annually. Becoming the world's largest single-site high-end PVA production base, the facility breaks foreign technology monopolies, replacing imports for high-value applications like optical films, pharmaceuticals, and electronics. **(ChemNet Chemical Headlines)**

Ganfeng Lithium Confirms 2 Million-Ton Potash Project in Congo for 2027

Ganfeng Lithium announced that its Bougoumassi potash project in the Republic of the Congo will be built as a single-stage 2-million-ton annual potassium chloride facility, targeted for 2027 production. Holding a 50% stake, the global lithium titan is expanding into potash to establish a second resource growth driver and strengthen international supply security. **(ChemNet Chemical Headlines)**